Skip to main content
Toggle navigation
Search
Home
Back
Favorite
0
Like
Facebook
Print
Session VIII: Esophageal and Gastric Cancers
LBA-1: RATIONALE-306: Randomized, global, Phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for locally advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC)
Thursday, June 30, 2022
11:04 – 11:16
Location: Auditorium A; Level 0
Abstract Presenter(s)
Harry Yoon
